All participants (irrespective of study arm) were asked to identify a quit date that was at least 15 days, but no more than 30 days, from their registration date.
Seventeen RCTs were identified, a mean quit rate of 13.19% and a sample-weighted average effect size of 0.33 were observed.
However, all participants identified that, once a quit attempt had started, NRT alone was not enough to maintain abstinence; self motivation, support from friends, family and formal support services such as the NHS SSS advisors were also important.
In the case of employment spells, each uncensored job spell is identified as either a layoff, a quit, a job-to-job transition to a permanent contract (hereafter JJ PC) or a job-to-job transition to a temporary contract (hereafter JJ TC).13 We include transitions with an observed unemployment spell of 15 days or less within job-to-job transitions.
In addition, participants will be asked to identify a treatment goal (quit or reduce gambling) and how successful they think they would be (0 "not at all" to 10 "extremely") in the next 6 months and in the next 12 months.
12 Identifying those who are more likely to make a quit attempt, may enable tailoring of messages and supportive approaches.
Calls focus on creating a quit plan, developing problem-solving and coping skills, identifying social support, and using cessation medications to achieve and maintain abstinence.
Break-even analysis was used to identify the quit rate required for the genetic test to be cost-effective compared with usual smoking-cessation.
Augmenting tobacco quitline treatment with IVR-delivered relapse risk screening assessments was acceptable to participants, and successfully identified recently quit tobacco users who may be in need of more intensive or different intervention.
The latter strategies include: (1) identifying and documenting tobacco use for every patient at every visit, (2) strongly urging every tobacco user to quit, determining the willingness of the tobacco user to make a quit attempt, using counseling and pharmacotherapy to aid patients in quitting, and scheduling follow-up contact [ 35, 36].
